The last quarter of 2023 was an exciting one for the cell and gene therapy sector – with the first-ever approval for a CRISPR-based therapeutic in the US and an increase in Phase III trials in the overall CGT pipeline. 

Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.

BioFire’s test detects a range of respiratory and bacterial infections, including SARS-CoV-2. Its clearance is the first example of how other products with EUAs can stay on the market after the pandemic.

The Swiss group is expanding its alliance with the Karolinska Institutet to conduct 10 studies designed to improve understanding of the microbiome’s impact on reproductive and gut health challenges.